drugset / Trial / NCT00036257
Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
Phase 1
Completed
15 enrolled
Astellas Pharma Inc
Cell Pathways · collabOSI Pharmaceuticals · collab
Non-randomizedOpen-labelTreatment
Summary
The purposes of this study are to determine a maximum tolerated dose and to evaluate the safety and efficacy of CP-461 in patients with Chronic Lymphocytic Leukemia.
Timeline
- Start
- 2002-03
- Primary completion
- —
- Completion
- 2003-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CP-461 | Small molecule | — | — |